Essen Amyloidosis Registry

NCT06887283 · tracked via the Priya Life Science Germany tracker

Sponsor

University Hospital, Essen

Phase

Observational

Started

2024-05-08

Last updated

2025-08-21

Condition(s) studied

Amyloidosis; SystemicAmyloidosis Cardiac

Study summary

The Essen Amyloidosis Registry (EAR) is a prospective, observational registry designed to collect comprehensive clinical data on patients diagnosed with systemic amyloidosis. The registry aims to improve the understanding of disease progression, diagnostic pathways, and treatment outcomes. The registry is hosted at the University Hospital Essen and follows patients longitudinally. Inclusion is open to all patients with suspected or confirmed amyloidosis who provide informed consent.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Accepted

Inclusion Criteria: * Suspected or confirmed amyloidosis (any) * Written informed consent to participate in the study * Age 18 years and above Exclusion Criteria: * Age \< 18 years * Lack of written informed consent

Primary outcome measure(s)

Overall mortality or unplanned hospitalization for heart failure — 24 months
Overall mortality or unplanned hospitalization for heart failure is defined as the primary endpoint. The time to the primary endpoint will be measured in days starting from the day of first diagnosis of cardiac amyloidosis.

Trial sites (1)

Facility	City	Region	Status
University Hospital Essen	Essen	North Rhine-Westphalia	Recruiting

More University Hospital, Essen trials in Germany

Tourniquet-Test in HHT Active, not recruiting

Essen Coronary Artery Disease Registry Recruiting

Proton vs. Photon Radiotherapy for Patients With WHO Grade 2-3 Glioma Recruiting

Body Donation in HHT Recruiting

Hybrid Florbetaben PET/MRI for Imaging of Cardiac Amyloidosis Recruiting

Other trials for the same condition

Non-Interventional Study on the Prevalence of Cardiac Amyloidosis in Patients With Higher-Grade Aortic Valve Stenosis - Evaluation Using Echocardiography, Computed Tomography, Tc99-SPECT/CT and Cardiac Magnetic Resonance Imaging (CMR) Recruiting

Screening, Characterization, and Longitudinal Follow-up of Patients With Cardiac Amyloidosis Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06887283 on ClinicalTrials.gov ↗ ← All trials in Germany